Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable…
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu…
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat…
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disordersAlprazolam, sold…
Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent…
Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's…
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the…
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11%…
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience…
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET…